Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Subscribe To Our Newsletter & Stay Updated